Newsroom 2005
Neurochem Inc. (NASDAQ: NRMX; TSX: NRM) announced today that its Independent Safety Review Board (ISRB) has issued a
third recommendation to continue the Company's North American Phase III clinical trial for Alzhemed™, an
investigational product candidate for the treatment of Alzheimer's disease (AD). The recommendation by the ISRB
members was based on their recent review of the safety data from 1,042 patients who have been on study medication
for an average of 20 weeks.
Neurochem's ISRB for Alzhemed™ is made up of independent medical experts who monitor and evaluate the safety of
patients taking part in the Alzhemed™ Phase III clinical trial in North America.
About Alzhemed™
Alzhemed™ has entered into a multicenter, randomized, double-blind, placebo-controlled, three-armed, parallel-design
Phase III clinical trial; 68 clinical centers have been enrolled in North America. A total of 1,052 patients have been
randomized to receive study medication over a period of 18 months. The Company also launched its Phase III clinical
trial in Europe in September 2005.
Alzhemed™ is an orally administered, small organic molecule that has been specifically designed to modify the
course of AD through its anti-amyloid activity. As part of a "disease modifying" novel class of product
candidates, Alzhemed™ is expected to act at two levels: by preventing and stopping the formation and the
deposition of amyloid fibrils in the brain and by binding to soluble Aß protein to reduce the amyloid-induced
toxicity on neuronal and brain inflammatory cells associated with amyloid build-up in AD.
About Neurochem
Neurochem is focused on the development and commercialization of innovative therapeutics for neurological disorders. The
Company's pipeline of proprietary, disease-modifying oral products addresses critical unmet medical needs.
1,3-propanedisulfonate (1,3PDS; Fibrillex™) is designated as an orphan drug, a Fast Track product candidate and
is also part of an FDA Continuous Marketing Applications Pilot 2 program. The Phase II/III clinical trial of
Fibrillex™ for the treatment of AA Amyloidosis was concluded in April 2005. The Company is in the process of
submitting a New Drug Application (NDA) for Fibrillex™ that the FDA has agreed to file and review.
3-amino-1-propanesulfonic acid (3APS; Alzhemed™), for the treatment of Alzheimer's disease, is in a North
American as well as European Phase III clinical trial and 3APS (Cerebril™), for the prevention of Hemorrhagic Stroke
caused by Cerebral Amyloid Angiopathy, has completed a Phase IIa clinical trial.
To Contact Neurochem
For additional information on Neurochem and its drug development programs, please call the North American toll-free number
1 877 680-4500 or visit our Web Site at: www.neurochem.com.
Certain statements contained in this news release, other than statements of fact that are independently verifiable
at the date hereof, may constitute forward-looking statements. Such statements, based as they are on the current
expectations of management, inherently involve numerous risks and uncertainties, known and unknown, many of which
are beyond Neurochem's control. Such risks include but are not limited to: the impact of general economic conditions,
general conditions in the pharmaceutical industry, changes in the regulatory environment in the jurisdictions in
which Neurochem does business, stock market volatility, fluctuations in costs, and changes to the competitive
environment due to consolidation, as well as other risks disclosed in public filings of Neurochem. Consequently, actual
future results may differ materially from the anticipated results expressed in the forward-looking statements. The
reader should not place undue reliance, if any, on the forward-looking statements included in this news release. These
statements speak only as of the date made and Neurochem is under no obligation and disavows any intention to update or
revise such statements as a result of any event, circumstances or otherwise. Please see the Annual Information Form for
further risk factors that might affect the Company and its business.
For further Information, please contact:
Dr. Lise Hébert
Vice President, Corporate Communications
lhebert@neurochem.com
275 Armand-Frappier
Laval (Quebec)
H7V 4A7
Tel: (450) 680-4500
Fax: (450) 680-4501
